{"protocolSection":{"identificationModule":{"nctId":"NCT00625131","orgStudyIdInfo":{"id":"NEUA-007-07F"},"organization":{"fullName":"VA Office of Research and Development","class":"FED"},"briefTitle":"Nicotine Patch Pretreatment for Smoking Cessation in PTSD","officialTitle":"Nicotine Patch Pre-treatment for Smoking Cessation in PTSD"},"statusModule":{"statusVerifiedDate":"2014-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-05"},"primaryCompletionDateStruct":{"date":"2013-03","type":"ACTUAL"},"completionDateStruct":{"date":"2013-03","type":"ACTUAL"},"studyFirstSubmitDate":"2008-02-19","studyFirstSubmitQcDate":"2008-02-19","studyFirstPostDateStruct":{"date":"2008-02-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-10-28","resultsFirstSubmitQcDate":"2014-11-12","resultsFirstPostDateStruct":{"date":"2014-11-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-11-12","lastUpdatePostDateStruct":{"date":"2014-11-20","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"US Department of Veterans Affairs","class":"FED"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study seeks to evaluate the relationship between PTSD, abstinence, and factors associated with relapse in the context of a randomized, clinical smoking cessation trial.","detailedDescription":"Smokers with PTSD will be randomly assigned to 1 of 2 pre-cessation patch therapy conditions (active patch versus placebo patch) for three weeks before a target quit-smoking date. All participants to will receive bupropion beginning 1 week prior to their quit day, given that they are medically eligible to be prescribed bupropion. All participants will receive a two session brief cognitive-behavioral therapy (CBT) session and will begin standard nicotine replacement therapy (NRT) on their quit day. PTSD symptoms, mood, and smoking craving will be carefully evaluated throughout the study using electronic diary assessments on personal digital assistants (PDA). Specifically, participants will carefully monitor their symptoms, mood, craving, and use of cigarettes using electronic diaries for one week prior to the pre-cessation period, during the 3-week pre-cessation treatment period, and 6 weeks post quit date. Since no previous study has examined factors associated with smoking abstinence following treatment among PTSD smokers10, predictors of treatment response will be examined. The study is designed to address the following items:\n\nSpecific Aim 1: To evaluate whether supplemental nicotine administration (i.e., pre-cessation treatment with nicotine patch and bupropion) will result in improved quit rates among smokers with PTSD.\n\nHypothesis 1.1 Supplemental nicotine administration during the pre-cessation period will result in improved quit rates in the first quit week over the placebo patch condition.\n\nSpecific Aim 2: To utilize electronic diary assessment of PTSD symptoms, mood, smoking craving, and smoking during baseline, pretreatment, and quit periods to evaluate potential mechanisms of how pretreatment with the nicotine patch may increase abstinence rates.\n\nHypothesis 2.1 Supplemental nicotine administration will decrease craving for cigarettes during the 2 week pretreatment period as compared to the placebo patch condition.\n\nHypothesis 2.2 Supplemental nicotine administration will decrease the perceived improvement in mood and PTSD symptoms associated with smoking behavior, i.e., symptom relief from ad lib smoking a cigarette will be reduced during supplemental nicotine administration as compared to the placebo patch condition.\n\nSpecific Aim 3: To investigate potential predictors of smoking abstinence and relapse associated with individual differences in affective style including anxiety sensitivity, measures of distress tolerance, and self-efficacy.\n\nHypothesis 3.1 Increased anxiety sensitivity will be predictive of shorter abstinence from smoking.\n\nHypothesis 3.2 Decreased distress tolerance will be predictive of shorter abstinence.\n\nHypothesis 3.3 Lower self-efficacy for smoking abstinence will be predictive of shorter abstinence.\n\nHypothesis 3.4 Increased PTSD symptoms severity and negative affect following the quit date will be associated with shorter abstinence."},"conditionsModule":{"conditions":["Stress Disorders, Posttraumatic","Tobacco Use Disorder"],"keywords":["Stress Disorders, Posttraumatic","Tobacco Use Disorder"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":87,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Active Nicotine Patch Group","type":"ACTIVE_COMPARATOR","description":"Transdermal nicotine patch","interventionNames":["Drug: Nicotine","Behavioral: Cognitive Behavioral Therapy for Smoking Cessation","Drug: Bupropion Sustained Release (SR)"]},{"label":"Placebo Patch Group","type":"PLACEBO_COMPARATOR","description":"Transdermal placebo patch","interventionNames":["Behavioral: Cognitive Behavioral Therapy for Smoking Cessation","Drug: Bupropion Sustained Release (SR)","Drug: Placebo patch"]}],"interventions":[{"type":"DRUG","name":"Nicotine","description":"Delivered through transdermal nicotine patch","armGroupLabels":["Active Nicotine Patch Group"]},{"type":"BEHAVIORAL","name":"Cognitive Behavioral Therapy for Smoking Cessation","description":"Manualized protocol for CBT in smoking cessation","armGroupLabels":["Active Nicotine Patch Group","Placebo Patch Group"],"otherNames":["CBT"]},{"type":"DRUG","name":"Bupropion Sustained Release (SR)","description":"Antidepressant","armGroupLabels":["Active Nicotine Patch Group","Placebo Patch Group"],"otherNames":["Zyban, Wellbutrin"]},{"type":"DRUG","name":"Placebo patch","description":"Pre-treatment placebo transdermal patch","armGroupLabels":["Placebo Patch Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Smoking Abstinence, Self-reported","description":"Number of participants by group reporting 1 week of self-reported abstinence in the week prior to Session 12 at six weeks post-treatment","timeFrame":"Week prior to Session 12 at 6 weeks post-treatment"}],"secondaryOutcomes":[{"measure":"Carbon Monoxide Monitoring","description":"Number of participants whose carbon monoxide (CO) measurement indicated abstinence at Session 12 (6 weeks post-treatment)","timeFrame":"Session 12 (6 weeks post-treatment)"},{"measure":"Smoking Craving","description":"Mean smoking craving score (as measured during daily ecological momentary, or diary, assessments) for participants by group during the two week period of placebo/active pre-treatment. This is the main period of interest, as it was hypothesized that use of active nicotine patch would reduce smoking cravings during the pre-quit period. The craving score is based on a single diary item \"Please rate your desire to smoke right now\" with a Likert scale score ranging from 1 (none) to 5 (severe). Higher craving is \"worse,\" as lower craving is presumed to reflect decreased risk of smoking lapse or relapse.","timeFrame":"Daily between visits 2-12"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Smokers who smoke 10 or more cigarettes per day in the past year;\n* 18-80 years old;\n* English speakers;\n* medically stable;\n* stable on current medication regimen\n\nExclusion Criteria:\n\n* Pregnant women excluded;\n* participants with organic mental disorder, schizophrenia, bipolar disorder, lifetime but not current PTSD, current substance abuse or dependence;\n* medical conditions contraindicated with nicotine replacement therapy;\n* use other forms of nicotine (cigars, nicotine gum, etc.)","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Jean C. Beckham, PhD","affiliation":"VA Medical Center, Durham","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"VA Medical Center, Durham","city":"Durham","state":"North Carolina","zip":"27705","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}}]},"referencesModule":{"references":[{"pmid":"29693495","type":"DERIVED","citation":"Dedert EA, Dennis PA, Calhoun PS, Dennis MF, Beckham JC. A Randomized Clinical Trial of Nicotine Preloading for Smoking Cessation in People with Posttraumatic Stress Disorder. J Dual Diagn. 2018 Jul-Sep;14(3):148-157. doi: 10.1080/15504263.2018.1468947. Epub 2018 Oct 10."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Active Nicotine Patch Group","description":"Transdermal nicotine patch\n\nNicotine: Delivered through transdermal nicotine patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant"},{"id":"FG001","title":"Placebo Patch Group","description":"Transdermal placebo patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant"},{"id":"FG002","title":"Not Randomized","description":"This arm includes patients who met screening criteria for entry into the randomization, but withdrew prior to randomization."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"44"},{"groupId":"FG002","comment":"These participants were not included in any analyses.","numSubjects":"5"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"42"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Arm 1","description":"Transdermal nicotine patch\n\nNicotine: Delivered through transdermal nicotine patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant"},{"id":"BG001","title":"Arm 2","description":"Transdermal placebo patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"82"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45.16","spread":"9.61"},{"groupId":"BG001","value":"44.48","spread":"11.31"},{"groupId":"BG002","value":"44.79","spread":"10.51"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"38"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"44"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"51"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"23"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"79"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"82"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Smoking Abstinence, Self-reported","description":"Number of participants by group reporting 1 week of self-reported abstinence in the week prior to Session 12 at six weeks post-treatment","populationDescription":"Any participants who did not attend Session 12 for any reason (i.e., lost to contact, withdrawn after beginning treatment) were counted as smoking (i.e., intent-to-treat analyses, missing = smoking).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week prior to Session 12 at 6 weeks post-treatment","groups":[{"id":"OG000","title":"Active Nicotine Patch Group","description":"Transdermal nicotine patch\n\nNicotine: Delivered through transdermal nicotine patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant"},{"id":"OG001","title":"Placebo Patch Group","description":"Transdermal placebo patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"44"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"11"}]}]}]},{"type":"SECONDARY","title":"Carbon Monoxide Monitoring","description":"Number of participants whose carbon monoxide (CO) measurement indicated abstinence at Session 12 (6 weeks post-treatment)","populationDescription":"Please note that this secondary outcome (bioverification by CO reading) is not a measure of complete smoking abstinence during the study period (or during the week prior to the session - see Primary Outcome). It is independent of self-reported smoking abstinence. It is not unexpected that CO readings different than self-reported smoking.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Session 12 (6 weeks post-treatment)","groups":[{"id":"OG000","title":"Active Nicotine Patch Group","description":"Transdermal nicotine patch\n\nNicotine: Delivered through transdermal nicotine patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant"},{"id":"OG001","title":"Placebo Patch Group","description":"Transdermal placebo patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"SECONDARY","title":"Smoking Craving","description":"Mean smoking craving score (as measured during daily ecological momentary, or diary, assessments) for participants by group during the two week period of placebo/active pre-treatment. This is the main period of interest, as it was hypothesized that use of active nicotine patch would reduce smoking cravings during the pre-quit period. The craving score is based on a single diary item \"Please rate your desire to smoke right now\" with a Likert scale score ranging from 1 (none) to 5 (severe). Higher craving is \"worse,\" as lower craving is presumed to reflect decreased risk of smoking lapse or relapse.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Daily between visits 2-12","groups":[{"id":"OG000","title":"Active Nicotine Patch Group","description":"Transdermal nicotine patch\n\nNicotine: Delivered through transdermal nicotine patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant"},{"id":"OG001","title":"Placebo Patch Group","description":"Transdermal placebo patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.48","spread":"1.40"},{"groupId":"OG001","value":"2.59","spread":"1.24"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"AE data were collected in real time during each participant session or contact from baseline to 6 month follow-up (ranging from one day to nine months). These data represent AEs reported by all participants over the entire 4 years of data collection.","description":"Serious AEs were reviewed with the PI immediately after they were reported to the study coordinator. Non-serious AEs were reviewed with the PI at weekly staff meetings.","eventGroups":[{"id":"EG000","title":"Active Nicotine Patch Group","description":"Transdermal nicotine patch\n\nNicotine: Delivered through transdermal nicotine patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant","seriousNumAffected":0,"seriousNumAtRisk":38,"otherNumAffected":12,"otherNumAtRisk":38},{"id":"EG001","title":"Placebo Patch Group","description":"Transdermal placebo patch\n\nCognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation\n\nBupropion SR: Antidepressant","seriousNumAffected":2,"seriousNumAtRisk":44,"otherNumAffected":16,"otherNumAtRisk":44}],"seriousEvents":[{"term":"Hospitalization for pre-existing Chronic Obstructive Pulmonary Disease (COPD)","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":44}]},{"term":"Hospitalization for preexisting circulatory disorder","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":44}]}],"otherEvents":[{"term":"nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":44}]},{"term":"Surgical Intervention, non-study related","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Several participants had minor surgical interventions during the course of the study that were not related to study participation.","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":44}]},{"term":"Exacerbation of pre-existing PTSD symptoms","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":38},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":44}]},{"term":"Sleep disturbance and/or increased nightmares","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":38},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":44}]},{"term":"Itching and/or skin rash at site of patch placement","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":38},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":44}]},{"term":"Orthopedic accident, not study related","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":44}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":44}]},{"term":"Gas and/or hemorrhoid pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":44}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Angela Kirby, MS; Regulatory Coordinator","organization":"VA Medical Center, Durham, NC","email":"angela.kirby@va.gov","phone":"9192860411","phoneExt":"5526"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D013313","term":"Stress Disorders, Post-Traumatic"},{"id":"D014029","term":"Tobacco Use Disorder"}],"ancestors":[{"id":"D040921","term":"Stress Disorders, Traumatic"},{"id":"D000068099","term":"Trauma and Stressor Related Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D019966","term":"Substance-Related Disorders"},{"id":"D064419","term":"Chemically-Induced Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D009538","term":"Nicotine"},{"id":"D015928","term":"Cognitive Behavioral Therapy"},{"id":"D016642","term":"Bupropion"}],"ancestors":[{"id":"D012991","term":"Solanaceous Alkaloids"},{"id":"D000470","term":"Alkaloids"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D011725","term":"Pyridines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D001521","term":"Behavior Therapy"},{"id":"D011613","term":"Psychotherapy"},{"id":"D004191","term":"Behavioral Disciplines and Activities"},{"id":"D011427","term":"Propiophenones"},{"id":"D007659","term":"Ketones"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}